| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Original Research Communication |
1 From the Department of Molecular and Human Genetics (FS, JH, and BL), the Department of Pediatrics (JR), Children’s Nutrition Research Center, and the Howard Hughes Medical Institute (BL), Baylor College of Medicine, Houston; the Department of Animal Sciences, University of Illinois-Urbana, Urbana, IL (JM and PR); and the Department of Surgery, Stony Brook University, Stony Brook, NY (PG).
2 Supported by grants DK56787 (to BL) and DK54450 (to PR) from the NIH, grant HD24064 from the Baylor College of Medicine Child Health Research Center, Mental Retardation Research Center, and grant RR00188 from the Texas Children’s Hospital General Clinical Research Center.
3 Dedicated to the memory of Peter Reeds.
Correspondence: 4 Address reprint requests to B Lee, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Room 630E, Houston, TX 77030. E-mail: blee{at}bcm.tmc.edu.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Objective: The objective of the study was to investigate whether females with symptomatic OTCD rely on alternative pathways to compensate for the reduced urea synthesis activity observed in this disorder.
Design: The 5-d study involved 6 control subjects (3 males, 3 females) and 6 female OTCD carriers who had a fixed energy intake of 133 kJ · kg-1 · d-1 and a protein intake of 0.8 g · kg-1 · d-1. They underwent two 12-h periods of isotopic tracer administration, separated by 2 d. On both occasions, [18O] or [13C]urea was infused intravenously, and the subjects consumed hourly meals. During the first period, [15N]NH4Cl was given intravenously; during the second period, the tracer was given as hourly oral doses.
Results: OTCD carriers produced less urea (P < 0.05) but had a higher (P < 0.05) mean ammonia appearance rate and plasma ammonia concentration than did control subjects. OTCD carriers incorporated a lower (P < 0.001) mean (± SE) proportion of the intravenous [15N]NH4Cl dose into circulating urea than did control subjects (16 ± 1% compared with 36 ± 2%), but there was no genotypic difference in the incorporation of orally administered tracer (81 ± 4% compared with 72 ± 4%, respectively).
Conclusion: A good degree of dietary protein tolerance seemed to be retained in OTCD carriers by the maintenance of higher ammonia appearance rates, expansion of the plasma ammonia pool, and reliance on the ability of the perivenous hepatocytes to clear excess ammonia via glutamine synthesis.
Key Words: Urea synthesis • humans • ammonia flux • ornithine transcarbamylase deficiency • stable isotopes
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
1:75 000 births) disorder of the urea cycle is ornithine transcarbamylase deficiency (OTCD; 1–3). Persons with OTCD have less ability to synthesize citrulline from ornithine and carbamoyl phosphate than do persons without OTCD. Because OTCD is an X-linked condition, the random nature of X chromosome inactivation results in a wide variation in the capacity for urea synthesis among female OTCD carriers. It is of particular interest that, whereas many OTCD carriers exhibit little dietary protein sensitivity (4, 5) and are not chronically hyperammonemic, the stability of their nitrogen metabolism is sensitive to stresses such as fasting and infection (6, 7) that accelerate the mobilization of protein stores. For example, clinically significant hyperammonemia can occur in otherwise asymptomatic female OTCD carriers during childbirth (5). These clinical observations imply that apparently asymptomatic OTCD carriers may harbor more subtle defects in nitrogen metabolism. This possibility is supported by our findings, which show that fed female asymptomatic OTCD carriers derive considerably less urea from glutamine amide-N than do control subjects, even though the OTCD carriers continue to have apparently adequate rates of urea synthesis (8). The 2 nitrogen atoms of urea, the final compound of mammalian nitrogen metabolism, are derived from separate intracellular precursors: one from free ammonia, incorporated via mitochondrial carbamoyl phosphate, and the other from aspartate-N, incorporated via the synthesis of cytosolic argininosuccinate (1). Although the intermediate extracellular precursors for hepatic ureagenesis are ammonia, glutamine, alanine, and glutamate (9–11), their relative contributions to urea synthesis remain incompletely characterized. Initial precursors also include other amino acids that are deaminated and transaminated in the liver. From a physiologic perspective, it is important to note that different extracellular precursors derive from different anatomical sites. Thus, peripheral (eg, muscle) amino acid metabolism generates glutamine and alanine (12), whereas intestinal amino acid metabolism generates ammonia and alanine (12, 13). The present study was designed to test the following 3 hypotheses: 1) enterally generated ammonia and peripherally generated ammonia are metabolized differently in OTCD carriers than in control subjects, 2) ammonia is cleared into urea less effectively in female OTCD carriers than in control subjects, and 3) glutamine is produced at a greater rate in females with OTCD than in control subjects to compensate for the OTCD carriers’ reduced ureagenic capacity. We compared the transfer of the nitrogen from intravenously and orally administered [15N]ammonium chloride to urea and simultaneously measured the total rate of urea synthesis with either [18O] or [13C]urea. This combination in the route of tracer administration allows for the quantification of the [15N]ammonia incorporated into urea, as well as the first-pass extraction (FPE) of the tracer by the liver.
|
SUBJECTS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Protocol
On admission, the subjects gave written informed consent, and blood was drawn for baseline clinical measurement of differential blood count, circulating hepatic enzymes, plasma amino acids, and plasma ammonia. The subjects were begun on a weighed diet for the duration of the study; it supplied the currently recommended intake of protein (0.8 g · kg-1 · d-1) and adequate nonprotein energy (32 kcal · kg-1 · d-1). The actual intakes were calculated for each day of the study and are reported in Table 1
. A urine pregnancy test was performed on all female subjects to rule out pregnancy.
|
On day 5, after another overnight fast and the removal of baseline samples, the subjects received a primed urea infusion as on day 3 and ingested a single oral dose of [15N]ammonium chloride (3 µmol/kg). Thereafter, the subjects ingested an oral dose of [15N]ammonium chloride (3.24 µmol · kg-1 · h-1) with each hourly meal starting at time 0.
Analysis
Plasma ammonia was measured with the use of a glutamate dehydrogenase enzyme assay on a clinical analyzer (Cobas Fara; Roche Products, Indianapolis). Plasma amino acids were measured by reversed-phase HPLC (Waters Technologies, Milford, MA) with the use of the phenylisothiocyanate derivative (13). An aliquot of plasma was mixed either with 4 volumes of acetone or with an equal volume of acetic acid (1 mol/L) for the determination of the isotopic enrichment of urea and glutamine, respectively. The enrichment of the plasma ammonia was determined on untreated plasma samples.
The isotopic enrichments of glutamine, ammonia, and [18O]urea were determined by selective ion-monitoring gas chromatography–mass spectrometry (GC-MS; Hewlett Packard, Palo Alto, CA). Glutamine was measured as the n-propyl ester of the heptafluorobutyramide derivative (14). Separation of the glutamine derivative was on an HP5 capillary column (Hewlett-Packard), and the labeling was assessed by scanning mass-to-charge ratios (m/z) of 346–348 after negative methane chemical ionization. The labeling of plasma ammonia was measured as described by Nieto et al (15). The method involves the synthesis of norvaline by reacting plasma ammonia with 2oxopentanoic acid in the presence of glutamate dehydrogenase. The resulting norvaline was then measured as the tertiary butyldimethylsilyl derivative, and its enrichment was assessed by scanning m/z ratios of 186–188 after electron impact ionization. Separation was effected on a model 1701 capillary column (J & W Scientific, Folsom, CA). Urea labeling was measured as the 2-pyrimidinol-tertiary butyldimethylsilyl derivative of urea. The derivative was prepared by incubating the sample for 2 h at 25 °C with 250 µL of an aqueous solution of malondialdehyde (700 mmol/L or 50 g/L) together with 25 µL HCl (11 mol/L). At the end of the incubation, the samples were dried under vacuum and mixed with 50 µL of a solution of tertiary butyldimethylsilane (800 mmol/L or 100 g/L) in ethyl acetate. The mixture was placed in a securely sealed vial and incubated at room temperature for 24 h. Separation of the derivative was effected on a 1701 capillary column (J & W Scientific), and labeling was assessed by scanning m/z 153–156 after electron impact ionization.
During the course of the study, [18O]urea became unavailable, and this prompted a change in the analytic approach. Thus, in 2 control subjects and 3 patients, the appearance rate of urea (URa) was measured with [13C]urea as the tracer. In these studies, the enrichment of urea was assessed, first, by using selective ion-monitoring GC-MS. From a separate plasma aliquot, urea was purified with the use of sequential cation [Dowex 50 (H+); Supelco, Bellafonte, PA) and anion [Dowex 2 (OH-); Supelco] chromatography. The purified urea sample was dried, derivatized as indicated above, and subjected to combustion GC-combustion isotope ratio MS (GC-CIRMS) performed with a GC-combustion isotope ratio mass spectrometer linked to an online combustion device (PDZ Europa, Sandbach, United Kingdom). The relative abundances of peaks with m/z 28 and 29 were used to determine the 15N content of the urea. The 13C enrichment was then determined by the difference between the abundance of the 187 ion (ie, 13C and 15N), as determined by selected ion-monitoring MS, and the [15N]urea enrichment, as determined by GC-CIRMS. Comparisons among the control subjects showed that the 2 estimates of the URa were not significantly different: URas determined with [18O]urea and with [13 C]urea were 208 ± 32 and 212 ± 33 µmol · kg-1 · h-1, respectively (P > 0.7). Likewise, the isotopic enrichment of [15N]urea determined with GC-MS [0.63 ± 0.11 mol percent excess (MPE)] was not significantly different (P > 0.5) from that determined with GC-CIRMS (0.56 ± 0.12 MPE).
Calculations
The URas and the appearance rates of ammonia (ARas) were calculated from the enrichment ([E]) resulting from intravenous infusion of the tracers according to the standard equation:
 | (1) |
The transfer of 15N from infused or ingested ammonia to urea was expressed as
 | (2) |
The fractional transfer of infused or ingested [15N]ammonia to urea was expressed as
 | (3) |
In addition, the amount of tracer that escapes FPE by the liver can be calculated as follows:
 | (4) |
where [E]Ammoniaoral is the enrichment of plasma ammonia when the tracer is administered orally.
The proportion of tracer escaping FPE is calculated as follows:
 | (5) |
When [15N]NH4Cl was infused intravenously, plasma glutamine reached an isotopic enrichment proportional to that of its precursor (plasma ammonia). According to this reasoning, the oral tracer that escapes the FPE and reaches the peripheral circulation will result in a similar proportional peripheral glutamine enrichment; thus:
 | (6) |
where [E]AmmoniaIV and [E]GlutamineIV are the enrichments of plasma ammonia and glutamine, respectively, when the tracer is administered intravenously.
When the [15N]NH4Cl was given orally, a higher peripheral [E]Glutamine was observed because of hepatic glutamine synthesis before [15N]NH4Cl reached the peripheral circulation. Although some glutamine might have been synthesized in the liver when [15N]NH4Cl was infused peripherally, a larger proportion of the dose was available for hepatic glutamine synthesis when the dose was given orally. This can be calculated as follows:
 | (7) |
Although the appearance rate of glutamine (GRa) was not determined in this study, the values reported by Lee et al (8) for control subjects (391 µmol · kg-1 · h-1) and asymptomatic OTCD subjects (379 µmol · kg-1 · h-1) on an identical protein level can be used to estimate the actual mass transfers of the ingested tracer:
 | (8) |
and
 | (9) |
and
 | (10) |
Because the tracer can be incorporated into other products in the liver besides glutamine, the exact amount of tracer incorporated into urea in FPE cannot be calculated, but the maximal amount can be estimated:
 | (11) |
Finally, both oral [15N]NH4Cl incorporated into glutamine by the liver and the maximal amount of tracer converted into urea in FPE can be calculated as a percentage of the dose by dividing Equation 10
and Equation 11 by the amount of tracer ingested, respectively.
Statistical analysis
The data were analyzed by one-way analysis of variance, with the route of ammonia administration and the genotype as independent variables. Post hoc pairwise comparisons, using the Tukey adjustment for multiple comparisons, were conducted. Values reported are means ± SEs (n = 6).
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. Although the plasma ammonia concentrations of the OTCD carrier group were within clinically acceptable limits, the mean concentration was higher (42 µmol/L; P < 0.05) than that in control subjects (26 µmol/L). The plasma concentrations of glutamine and alanine showed no significant genotypic difference (results not shown).
The 18O or 13C and 15N isotopic enrichments of urea are shown in Figure 1. Plasma ammonia (Figure 1), as well as plasma glutamine (data not shown), had reached an isotopic steady state by 8 h of infusion.
|
. Separate mass spectrometric measurements of a fragment of the glutamine derivative that contained only the amino-N group showed that 86 ± 6% of the 15N in glutamine was in the amide group. In addition, during the intravenous ammonia infusion, the isotopic enrichment of plasma [15N]glutamate was only 10% of that of glutamine amide-N (data not shown).
|
); in contrast, during the oral administration of the tracer, the isotopic enrichment of circulating ammonia was significantly (P < 0.01) higher. This indicates that OTCD subjects had higher ARa and a lower extraction of the tracer, in its first pass by the liver, than did control subjects (Table 3).
|
).
No difference (P > 0.92) in urea production between the 2 infusion days (days 3 and 5) was observed in control subjects and OTCD carriers when the data were calculated to pool the marginal means of days 3 and 5 (Table 3). A significantly higher (P < 0.001) URa was detected in control subjects (218 ± 31 µmol · kg-1 · h-1) than in OTCD carriers (177 ± 17 µmol · kg-1 · h-1). It was of particular interest that, in OTCD carriers, there was a significant (r = 0.88) negative linear relation between the circulating ammonia concentration and the URa (Figure 2). No relation between these variables was apparent in the control subjects (r = 0.12; data not shown).
|
). In both groups, the fractional transfer of ammonia-N to urea was higher (P < 0.001) when the ammonia tracer was given orally. Importantly, the difference between the incorporation of intravenous and oral ammonia nitrogen into urea was greater (P < 0.025) in the OTCD carriers (+ 400%) than in the control subjects (100%). As a consequence, there was a highly significant (P < 0.001) interaction between genotype and route of administration with regard to the utilization of the 2 sources of ammonia for urea synthesis.
The fate of the oral dose of [15N]NH4Cl is shown in Figure 3. Because the ARa into the splanchnic circulation was not determined, we were unable to measure the actual mass transfer of tracee. A significantly (P < 0.001) larger proportion of the tracer escaped the FPE by liver either as ammonia or glutamine in OTCD carriers than in control subjects, which resulted in a lower (P < 0.001) incorporation into urea in the OTCD carriers.
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Animal studies in the past decade (13, 14, 18) and earlier (19) support the idea that at least three-quarters of the dietary amino acids that undergo intestinal catabolism, a process that may account for 35% of whole-body amino acid catabolism, are presented to the liver as hepatic portal venous ammonia. The present study was designed to test the general hypothesis that OTCD carriers handle this enteral ammonia source for urea synthesis differently than do control subjects. An earlier study from our laboratory (8) showed that patients with partial defects in urea synthesis appeared to utilize less glutamine as a nitrogen source for urea synthesis than did control subjects. It is known that OTCD carriers have a reduced capacity for urea synthesis; the results of the present study largely confirmed the hypothesis that there are marked differences between the ways that OTCD carriers and non-OTCD carriers metabolize nitrogen. In this study, we showed that FPE of the tracer was higher for control subjects than for OTCD carriers, OTCD carriers incorporated a larger proportion of the tracer into glutamine in the liver than did control subjects, and, despite the fact that their maximal incorporation of the tracer into urea in FPE was only 11%, OTCD carriers were able to incorporate as much as 81% of the tracer dose into urea.
Our results also showed a reduced FPE of the orally administered tracer in OTCD carriers and incorporation of a low proportion of the intravenous dose into urea. Although there are very few other human studies comparing the in vivo utilization of peripheral and enteral ammonia for urea synthesis (20, 21), particularly with subjects in the fed state (20), this limited literature largely supports the present observations. An almost complete FPE of portal ammonia was previously reported in humans (20), as was a large incorporation of oral ammonia into nonessential amino acids (21). This ability to retain ammonia-N in amino acids could benefit OTCD carriers in subsequently directing the nitrogen into urea, which would account for the incorporation of 81% of tracer into urea that we observed in the OTCD carriers. It seems highly likely that, as expected from the metabolic properties of the periportal hepatocytes (20), the extraction of portal ammonia by the liver in control subjects is primarily, although not exclusively, channeled to urea synthesis, as indicated by a 61% FPE of the oral tracer into urea. In contrast, because of the lesser ability of OTCD carriers than of non-OTCD carriers to detoxify ammonia, more tracer escaped periportal urea synthesis and was converted into glutamine by the perivenous hepatocytes. It was also reported previously that there is a substantial difference in the metabolic fate of ammonia, depending on the route of tracer administration (21). This finding agrees with our observations. The reason for this difference is not clear (21); it could derive from a number of mechanisms (eg, clearance of ammonia by the kidney or preferential incorporation of newly synthesized amino acid), and it warrants further investigation.
These results add evidence that asymptomatic OTCD carriers have to rely on alternative pathways to temporarily detoxify ammonia before it is incorporated into urea. Thus, a good degree of dietary protein tolerance appears to be maintained in OTCD carriers through the maintenance of higher ARa, expansion of the plasma ammonia pool to levels closer to the upper normal limit, and reliance on the ability of perivenous hepatocytes to clear excess ammonia via glutamine synthesis. Although these alternative pathways seem to be successful in handling ammonia, they are also very fragile, as indicated by the hyperammonemic episodes that characterize the disorder. This fact reinforces the importance of preventing sudden changes in nitrogen metabolism in patients with defects in the urea cycle, either by minimizing their exposure to conditions, such as infection, that increase peripheral protein catabolism or by avoiding drastic changes in dietary protein intake.
|
ACKNOWLEDGMENTS |
|---|
PR and BL collaborated in the design of the study. FS, BL, and PR implemented the study. FS and BL participated in the data collection. JH and JR participated in the sample analysis and data collection. All authors participated in the data analysis. PR, BL, JM, PG, and FS participated in the discussion and together prepared the manuscript. None of the authors had any conflict of interest.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  J. C. Marini, B. Lee, and P. J. Garlick In Vivo Urea Kinetic Studies in Conscious Mice J. Nutr., January 1, 2006; 136(1): 202 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Scaglia, N. Brunetti-Pierri, S. Kleppe, J. Marini, S. Carter, P. Garlick, F. Jahoor, W. O'Brien, and B. Lee Clinical Consequences of Urea Cycle Enzyme Deficiencies and Potential Links to Arginine and Nitric Oxide Metabolism J. Nutr., October 1, 2004; 134(10): 2775S - 2782S. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
, intragastric study in control subjects; •, intravenous study in control subjects; 
, intragastric study in ornithine transcarbamylase deficiency (OTCD) carriers; and 
, intravenous study in OTCD carriers. The plasma ammonia pool was at isotopic steady state by 8 h of infusion. The isotopic enrichment of both [18O] or [13C]urea and [15N]urea rose at a nonsignificant rate of 2%/h from 0800 to 1200. MPE, mol percent excess.
